Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
Company Details
- Employees
- 208
- Founded
- -
- Address
- One Broadway 14th Floor, Cambridge,massachusetts 02142,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nuvalent.com/
- Keywords
- jobs.
- HQ
- Cambridge, Massachusetts
Nuvalent, Inc. Questions
Nuvalent, Inc.'s website is https://www.nuvalent.com/
Nuvalent, Inc.'s LinkedIn profile is https://www.linkedin.com/company/nuvalent-inc
Nuvalent, Inc. has
208 employees.
View email and phone details for 208
employees at Nuvalent, Inc..
Nuvalent, Inc.'s industry is
Biotechnology Research
Nuvalent, Inc.'s top competitors are
Quiver Bioscience,
Gc Therapeutics,
Rapport Therapeutics,
Bicara Therapeutics,
Fable Therapeutics,
Dyno Therapeutics,
Tessera Therapeutics,
Kalvista Pharmaceuticals, Inc.,
Myrobalan Therapeutics,
Delphia Therapeutics.
Nuvalent, Inc.'s categories are Biotechnology Research
Nuvalent, Inc.'s founding year is 2017
